Table 3 Odds of Outcomes Associated with Cinacalcet Treatment in Chronic Kidney Disease Patients, Stockholm, Sweden 2006–2012.

From: Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism

 

Crude OR (n = 3526)

Model 1* (n = 3339)

Model 2 ** (main)(n = 3339)

Model 3# (n = 3339)

Cardiovascular event

1.01 (0.83–1.22)

0.52 (0.34–0.81)

0.67 (0.48–0.93)

0.68 (0.51–0.92)

All-cause mortality

0.98 (0.82–1.19)

0.73 (0.49–1.07)

0.79 (0.56–1.11)

0.83 (0.62–1.10)

Fracture

1.15 (0.80–1.67)

1.06 (0.58–1.95)

1.08 (0.59–1.98)

1.15 (0.67–1.97)

  1. All results presented as Odds ratios OR) with 95% confidence intervals. Only months with complete information are included.
  2. Cardiovascular event (non-fatal or fatal myocardial infarction, cerebrovascular event, angina, congestive heart failure or peripheral arterial disease). *Fully-weighted model with no truncation of weights and adjustment for baseline variables in the MSM, **Fully-weighted model with truncation at 1,99th percentile and adjustment for baseline variables in the MSM, #Fully-weighted model with truncation at 1,99th percentile without adjustment for baseline variables in the MSM.
  3. The adjustment variables included in the stabilized weights (treatment and censoring weights) are presented in the Web Appendix. In short they included history of comorbid conditions, age and sex, routine laboratory variables at inclusion and monthly during follow-up, relevant medication at inclusion and monthly during follow-up, Charlson comorbidity index at inclusion and during follow-up, PTH-assay, dialysis and transplantation, and treatments 3–12 months before the current month.
Back to article page